Recent dealmaking, clinical and regulatory milestones show the field moving from broad immune modulation toward mechanism-led, precision-clearance and layered treatment strategies.
Updated September 2026VYVGART's continued growth shows how mechanism selection, administration experience and platform expansion can amplify the value of innovative immunotherapy. In kidney disease, the next step is to carry this logic into layered intervention across the pathogenic cascade and organ-precise delivery.
Lilly's proposed acquisition of Merida signals that selective pathogenic-antibody clearance is moving from a platform concept toward clinical and industry validation.
Read Podigy's industry perspective ↗A Nature study introduces the BTR strategy and PhoPEx chemistry, offering a new framework for targeted conjugates against poorly internalizing membrane proteins.
Read Podigy's industry perspective ↗The U.S. FDA granted accelerated approval to sibeprenlimab-szsi, an APRIL blocker, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
View primary source ↗Iptacopan, a factor B inhibitor, received U.S. accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
View primary source ↗The U.S. FDA granted accelerated approval to atrasentan to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
View primary source ↗The KDIGO 2025 guideline integrates newer supportive and targeted therapies and emphasizes preventing IgA-containing immune-complex injury while managing downstream kidney damage.
View primary source ↗Industry intelligence for scientific communication only. Approval status and indications vary by country or region; accelerated approvals may require confirmatory evidence.
